Breakthroughs in treating NSCLC: Targeting KRAS

touchTALKS for touchONCOLOGY Listen to Dr Christine Bestvina, as she evaluates the latest data on KRAS mutations in NSCLC and explores how emerging evidence for targeted therapies could influence clinical decision-making. The expert Dr Christine Bestvina, University of Chicago, Chicago, IL, USA This touchPODCAST is for HCPs outside of the UK. This activity is funded by an independent medical education grant from Revolution Medicines. This activity is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.  For further information visit our website: www.touchONCOLOGY.com